Raloxifene Hydrochloride Breast Cancer
Alias: Raloxifene HCl; KEOXIFENE; AKOS 92138
Appearance: Light yellow powder
Related Substances: Pharmaceutical Grade
Storage: Shading, confined preservation
Usage: It is used in the prevention of osteoporosis in postmenopausal women.
For bodybuilding purposes Adipex-P is often administered during the pre-contest phase of training. When taken in conjunction with all the pre-contest principles that would be employed anyway, i. e. Cardio and weight training exercise, behavioral modification, caloric restriction, increased protein consumption, etc., Adipex-P can be a great addition to the carbohydrate craving/depleted diet regimen.
The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1-2 hours after breakfast. Bodybuilder dosage recommendations are consistent with those of patients, and should be individualized to obtain an adequate response with the lowest effective dose. For some patients or bodybuilders half a tablet (18.75 mg) daily may be adequate, while others might take half a dose twice daily.
Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
White &off-white powder
Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water
Loss on drying
Residue on ignition
Any unspecified individual impurity 2
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
FDA approved raloxifene hydrochloride for the treatment and prevention of postmenopausal women with osteoporosis, reduces postmenopausal women with osteoporosis risk of invasive breast cancer, and reduces the risk of invasive breast cancer in postmenopausal women Risk of breast cancer.
The recommended dose is 60 mg tablets per day, regardless of diet. Male athletes and bodybuilders usually take 30 mg to 60 mg daily when using (off-label) to relieve estrogen side effects of synthetic metabolic / androgen steroids.